Virpax Pharmaceuticals News

Analysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)

TipRanksFeb 8 15:10 ET

Promising Pipeline Developments and Market Opportunities Drive Buy Rating for Virpax Pharmaceuticals

TipRanksNov 17, 2023 10:26 ET

Analysts Are Bullish on These Healthcare Stocks: Virpax Pharmaceuticals (VRPX), Kura Oncology (KURA)

TipRanksSep 28, 2023 12:10 ET

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Virpax Pharmaceuticals (VRPX)

TipRanksSep 19, 2023 11:11 ET

Maxim Group Remains a Buy on Virpax Pharmaceuticals (VRPX)

TipRanksAug 15, 2023 12:55 ET

Maxim Group Sticks to Their Buy Rating for Virpax Pharmaceuticals (VRPX)

TipRanksMay 16, 2023 12:45 ET

Maxim Group Keeps Their Buy Rating on Virpax Pharmaceuticals (VRPX)

TipRanksApr 6, 2023 12:35 ET

Analysts' Top Healthcare Picks: Xenetic Biosciences (XBIO), Virpax Pharmaceuticals (VRPX)

TipRanksMar 23, 2023 12:12 ET

Maxim Group Reaffirms Their Buy Rating on Virpax Pharmaceuticals (VRPX)

TipRanksFeb 14, 2023 11:11 ET

Virpax Pharmaceuticals (VRPX) Receives a Buy From Maxim Group

TipRanksDec 16, 2022 07:40 ET

Maxim Group Sticks to Its Buy Rating for Virpax Pharmaceuticals (VRPX)

TipRanksNov 11, 2022 11:55 ET

Maxim Group Sticks to Their Buy Rating for Virpax Pharmaceuticals (VRPX)

TipRanksAug 16, 2022 14:35 ET

Maxim Group Initiates Coverage on Virpax Pharmaceuticals With Buy Rating, $4 Price Target

MT NewswiresJun 9, 2022 10:31 ET

Virpax Pharmaceuticals Price Target Announced at $4.00/Share by Maxim Group

Dow JonesJun 9, 2022 09:31 ET

Virpax Pharmaceuticals Initiated at Buy by Maxim Group

Dow JonesJun 9, 2022 09:31 ET

Virpax Pharmaceuticals analyst ratings

Benzinga Analyst RatingsJun 9, 2022 09:22 ET

Maxim Group Initiates Coverage On Virpax Pharmaceuticals with Buy Rating, Announces Price Target of $4

Benzinga Real-time NewsJun 9, 2022 09:22 ET